publication venue for
- Cutaneous melanoma arising in a burn scar: two recent cases and a review of the literature. 2006
- Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.. 32. 2022
- Uveal melanoma metastatic at initial diagnosis: a case series.. 32. 2022
- Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases.. 32. 2022
- Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma.. 31. 2021
- Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).. 31. 2021
- Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma.. 30. 2020
- Assessment of internet sources on subungual melanoma.. 30. 2020
- Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.. 30. 2020
- Impact of initial stage on metastatic melanoma survival.. 29. 2019
- Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.. 27. 2017
- A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.. 26. 2016
- Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery.. 23. 2013
- Prognostic significance of drainage to pelvic nodes at sentinel lymph node mapping in patients with extremity melanoma.. 23. 2013
- c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.. 22. 2012
- Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial.. 19. 2009
- Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to metastatic melanoma tumors with wide range of melanin concentrations.. 17. 2007
- Surgical margins in patients with cutaneous melanoma--assessing the adequacy of excision.. 15. 2005
- The association between large congenital melanocytic naevi and cutaneous melanoma: preliminary findings from an Internet-based registry of 379 patients.. 15. 2005
- Randomized, placebo-controlled pilot trial of the effects of alpha-tocopherol supplementation on levels of autoantibodies against 5-hydroxymethyl-2-deoxyuridine in melanoma patients.. 14. 2004
- Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens.. 13. 2003
- Phase I trial of high dose paracetamol and carmustine in patients with metastatic melanoma.. 13. 2003
- Use of and beliefs about dermoscopy in the management of patients with pigmented lesions: a survey of dermatology residency programmes in the United States.. 12. 2002
- Clinical results using biochemotherapy as a standard of care in advanced melanoma.. 12. 2002
- Detection of intraepidermal malignant melanoma in vivo by confocal scanning laser microscopy.. 12. 2002
- Use of and beliefs about baseline photography in the management of patients with pigmented lesions: a survey of dermatology residency programmes in the United States.. 12. 2002
- Randomized, placebo-controlled trial of dietary supplementation of alpha-tocopherol on mutagen sensitivity levels in melanoma patients: a pilot trial.. 12. 2002
- Rarity of CDK4 germline mutations in familial melanoma.. 12. 2002
- Suppression of macrophage nitric oxide production by melanoma: mediation by a melanoma-derived product.. 11. 2001
- Cytokine production by CD4+ T-cells responding to antigen presentation by melanoma cells.. 9. 1999
- Mutation and expression of the low affinity neurotrophin receptor in human malignant melanoma.. 6. 1996
- Mutation and expression of the p53 gene in human malignant melanoma.. 4. 1994
- Treatment with high dose mouse monoclonal (anti-GD3) antibody R24 in patients with metastatic melanoma.. 2. 1992
- GNAQ and GNA11 mutations in uveal melanoma. 2014
- Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. 1997
- Isolation limb perfusion for melanoma: current trends and future directions. 1994